233 related articles for article (PubMed ID: 7846017)
1. Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer.
Yasue M; Sakamoto J; Teramukai S; Morimoto T; Yasui K; Kuno N; Kurimoto K; Ohashi Y
Pancreas; 1994 Nov; 9(6):735-40. PubMed ID: 7846017
[TBL] [Abstract][Full Text] [Related]
2. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
3. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
4. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
5. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer.
Ishigami S; Natsugoe S; Hokita S; Che X; Tokuda K; Nakajo A; Iwashige H; Tokushige M; Watanabe T; Takao S; Aikou T
J Clin Gastroenterol; 2001 Jan; 32(1):41-4. PubMed ID: 11154168
[TBL] [Abstract][Full Text] [Related]
6. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
7. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.
Kanda M; Fujii T; Takami H; Suenaga M; Inokawa Y; Yamada S; Nakayama G; Sugimoto H; Koike M; Nomoto S; Kodera Y
Surg Today; 2014 Sep; 44(9):1692-701. PubMed ID: 24114022
[TBL] [Abstract][Full Text] [Related]
8. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
Takahashi Y; Takeuchi T; Sakamoto J; Touge T; Mai M; Ohkura H; Kodaira S; Okajima K; Nakazato H;
Gastric Cancer; 2003; 6(3):142-5. PubMed ID: 14520526
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
11. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.
van Manen L; Groen JV; Putter H; Vahrmeijer AL; Swijnenburg RJ; Bonsing BA; Mieog JSD
Biomarkers; 2020 Mar; 25(2):186-193. PubMed ID: 32009482
[No Abstract] [Full Text] [Related]
12. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
13. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
[TBL] [Abstract][Full Text] [Related]
14. Utility of tumor markers in determining resectability of pancreatic cancer.
Schlieman MG; Ho HS; Bold RJ
Arch Surg; 2003 Sep; 138(9):951-5; discussion 955-6. PubMed ID: 12963650
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
Yang XQ; Chen C; Wang FB; Peng CW; Li Y
Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
[TBL] [Abstract][Full Text] [Related]
16. Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer.
Suzuki S; Shimoda M; Shimazaki J; Maruyama T; Oshiro Y; Nishida K; Sahara Y; Nagakawa Y; Tsuchida A
Eur Surg Res; 2018; 59(5-6):329-338. PubMed ID: 30453288
[TBL] [Abstract][Full Text] [Related]
17. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes.
Pezzilli R; Calculli L; Melzi d'Eril G; Barassi A
Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):553-557. PubMed ID: 27733327
[TBL] [Abstract][Full Text] [Related]
18. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
[TBL] [Abstract][Full Text] [Related]
19. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer.
Liu L; Xu H; Wang W; Wu C; Chen Y; Yang J; Cen P; Xu J; Liu C; Long J; Guha S; Fu D; Ni Q; Jatoi A; Chari S; McCleary-Wheeler AL; Fernandez-Zapico ME; Li M; Yu X
Int J Cancer; 2015 May; 136(9):2216-27. PubMed ID: 25273947
[TBL] [Abstract][Full Text] [Related]
20. Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma.
Tokunaga R; Imamura Y; Nakamura K; Uchihara T; Ishimoto T; Nakagawa S; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Oyama S; Shono T; Naoe H; Saeki H; Oki E; Watanabe M; Sasaki Y; Maehara Y; Baba H
Cancer Med; 2015 Nov; 4(11):1659-66. PubMed ID: 26310928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
